CME Presentations

Joslin Diabetes and Kidney Disease



  • Eugene Wright, MD

    Eugene Wright, MD

    Eugene Wright, MD

    Medical Director, Primary Care and Specialty Practices

    Eugene E. Wright, Jr., MD, graduated from Duke University School of Medicine, Durham, NC, and currently works for South Piedmont AHEC as well as serves as Consulting Associate for the university’s Department of Medicine. He serves as an Associate Editor for the Clinical Diabetes medical journal in addition to several other advisory and editorial boards. Dr. Wright is the inaugural chair of the ADA’s Primary Care Interest Group, a member of the ADA/AHA Know Diabetes by Heart initiative, and a member of the planning committee for the ADA’s annual Clinical Update Conference. He has published several articles on diabetes diagnosis, treatment and management and has given presentations at national and international meetings on new treatments and technology for diabetes.
  • Robert Stanton, MD

    Robert Stanton, MD

    Robert Stanton, MD

    Chief, Kidney and Hypertension Section

    Robert C. Stanton, M.D., is Chief of the Kidney and Hypertension Section at the Joslin Diabetes Center and an Associate Professor of Medicine at Harvard Medical School, Boston, MA. His research has focused on the essential enzyme G6PD and how its dysregulation affects the pathogenesis of many diabetic- and kidney-related diseases. Dr. Stanton serves on the Professional Practice Committee of the American Diabetes Association and is the Chair of the Chronic Kidney Guidelines Section. He is also the recipient of three honorary professorships as well as a lifetime achievement teaching award for Sustained Excellence in Teaching from Harvard Medical School.
  • Katherine Tuttle, MD, FASN, FACP, FNKF

    Katherine Tuttle, MD, FASN, FACP, FNKF

    Katherine Tuttle, MD, FASN, FACP, FNKF

    Executive Director for Research

    Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health, Regional Principal Investigator of the Institute of Translational Health Sciences, and Professor of Medicine at the University of Washington. Dr. Tuttle earned her medical degree from Northwestern University in Chicago, IL. Her major research interests are in diabetes and chronic kidney disease, and she has published over 300 original peer-reviewed articles. Dr. Tuttle also serves as chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology. She has received many honors and awards including the Medal of Excellence from the American Association of Kidney Patients and the Garabed Eknoyan Award from the National Kidney Foundation.

CME Information

Joslin Logo PQH Logo
New ADA and KDIGO Expert Guidance on the Management of Diabetes: The Role of PCPs in Facilitating Access to Evidence-based Care and Reducing Kidney-Function Decline
Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO)


This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.


Joslin Diabetes Center designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The enduring material will be available from July 31, 2023-July 31, 2024.


At the conclusion of this activity, participants will be able to:
  • Discuss strategies to provide people with diabetes access to recommended kidney-function screening
  • Summarize the differences in mechanisms of action between nsMRAs and steroidal MRAs, as well as the safety and efficacy data on nsMRAs and kidney and cardiovascular health in people with type 2 diabetes
  • Explain the rationale for recommending SGLT2 inhibitors for the management of people with type 2 diabetes and kidney disease


The primary target audience for this activity are US-based primary care physicians, NPs, and PAs. The secondary target audience for this activity are endocrinologists, diabetes educators, nephrologists.


There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that these modules will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.

Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.

The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.

The faculty and planning committee members for this program have disclosed the following:

  • Robert C. Stanton, MD*†, Chief, Kidney & Hypertension Section, Joslin Diabetes Center, Associate Professor of Medicine, Harvard Medical School, has no relevant financial relationships
  • Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director for Research, Providence Inland Northwest Health, Professor of Medicine, University of Washington is a consultant for Bayer, Boehringer Ingelheim, Novo Nordisk, and Travere
  • Eugene Edward Wright Jr., MD, Medical Director for Performance Improvement, South Piedmont AHEC, Consulting Associate, Department of Medicine, Duke University Medical Center, is a consultant for Renalytix and a consultant and speaker for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Sanofi
Planning Committee
  • Dr. Richard S. Beaser*, Senior Staff Physician and Medical Director of CME, Joslin Diabetes Center, has no relevant financial relationships with regard to this activity.
  • Vandana Gupta, Medical Director, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.
  • Jaimee Harris-Gold, Program Manager, PlatformQ Health Education, has no relevant financial relationships with regard to this activity.
Joslin CME Advisory Committee
  • Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center, has no relevant financial relationships.
  • Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center, holds stock in Tandem Diabetes Care.
  • Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center, is a consultant for Conversa Health.
  • Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center, has no relevant financial relationships
  • Elena Toschi, MD, Staff Physician, Joslin Diabetes Center, has no relevant financial relationships.
* Also on the Planning Committee
† Also on the CME Advisory Committee


Please send content inquiries to:

For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, CardioCareLive, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.